NASDAQ:BIOC Biocept (BIOC) Stock Forecast, Price & News $2.13 +0.08 (+3.90%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.02▼$2.1750-Day Range$2.05▼$10.9152-Week Range$1.99▼$47.70Volume50,868 shsAverage Volume89,362 shsMarket Capitalization$1.26 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Biocept MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside5,533.8% Upside$120.00 Price TargetShort InterestHealthy1.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 stars 3.0 Analyst's Opinion Consensus RatingBiocept has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $120.00, Biocept has a forecasted upside of 5,533.8% from its current price of $2.13.Amount of Analyst CoverageBiocept has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.32% of the float of Biocept has been sold short.Short Interest Ratio / Days to CoverBiocept has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biocept has recently decreased by 24.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiocept does not currently pay a dividend.Dividend GrowthBiocept does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOC. Previous Next 2.4 News and Social Media Coverage News SentimentBiocept has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biocept this week, compared to 2 articles on an average week.Search Interest4 people have searched for BIOC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Biocept to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biocept insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.39% of the stock of Biocept is held by insiders.Percentage Held by InstitutionsOnly 10.04% of the stock of Biocept is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Biocept is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biocept is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiocept has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biocept (NASDAQ:BIOC) StockBiocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.Read More Receive BIOC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOC Stock News HeadlinesJune 2, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Research Coverage Started at StockNews.comJune 1, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Biocept (NASDAQ:BIOC)June 2, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 26, 2023 | benzinga.comBiocept shares are trading lower after the company announced pricing of a $5 million underwritten public offering.May 26, 2023 | marketwatch.comBiocept Shares Sink After Public Offering PricingMay 25, 2023 | msn.comBiocept stock surges on pricing $5.0M stock offeringMay 24, 2023 | markets.businessinsider.comBiocept Announces Pricing Of $5 Mln Underwritten Public OfferingMay 24, 2023 | finance.yahoo.comBiocept Announces Pricing of $5.0 Million Underwritten Public OfferingJune 2, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>May 23, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Coverage Initiated by Analysts at StockNews.comMay 17, 2023 | benzinga.comBiocept shares are trading lower after the company announced a 1-for-30 reverse stock split. The stock began trading on a split-adjusted basis today.May 17, 2023 | proactiveinvestors.comBiocept shares to commence trading on split-adjusted basisMay 17, 2023 | marketwatch.comBiocept Begins Trading on Reverse Split Adjusted Basis, Shares FallMay 17, 2023 | finance.yahoo.comBiocept Announces One-for-Thirty Reverse Stock SplitMay 15, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Receives New Coverage from Analysts at StockNews.comMay 12, 2023 | morningstar.comBiocept Inc BIOC Stock QuoteMay 12, 2023 | msn.comBiocept GAAP EPS of -$0.41, revenue of $0.7M misses by $0.88MMay 12, 2023 | finance.yahoo.comBiocept First Quarter 2023 Earnings: US$0.41 loss per share (vs US$0.16 loss in 1Q 2022)May 11, 2023 | proactiveinvestors.comBiocept ends 1Q with $6.8M cash; 'exceptionally pleased' with FORESEE clinical trial progressMay 10, 2023 | finance.yahoo.comBiocept Reports First Quarter 2023 Financial ResultsMay 8, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Coverage Initiated at StockNews.comApril 22, 2023 | americanbankingnews.comBiocept (NASDAQ:BIOC) Now Covered by StockNews.comApril 19, 2023 | finance.yahoo.comThere's No Escaping Biocept, Inc.'s (NASDAQ:BIOC) Muted Revenues Despite A 49% Share Price RiseApril 18, 2023 | msn.comBiocept GAAP EPS of -$1.89 misses by $0.84, revenue of $25.9M beats by $18.65MApril 18, 2023 | proactiveinvestors.comBiocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial yearApril 17, 2023 | finance.yahoo.comBiocept Reports 2022 Financial ResultsApril 15, 2023 | msn.comMaxim Group Downgrades Biocept (BIOC)See More Headlines BIOC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOC Company Calendar Last Earnings11/15/2021Today6/02/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC CUSIPN/A CIK1044378 Webwww.biocept.com Phone(858) 320-8200Fax858-320-8225Employees104Year Founded1993Price Target and Rating Average Stock Price Forecast$120.00 High Stock Price Forecast$120.00 Low Stock Price Forecast$120.00 Forecasted Upside/Downside+5,481.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($64.2642) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,090,000.00 Net Margins-32.99% Pretax Margin-564.02% Return on Equity-235.66% Return on Assets-94.87% Debt Debt-to-Equity Ratio0.42 Current Ratio2.07 Quick Ratio1.91 Sales & Book Value Annual Sales$25.86 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.52Miscellaneous Outstanding Shares590,000Free Float584,000Market Cap$1.27 million OptionableOptionable Beta0.94 Social Links Key ExecutivesSamuel D. RiccitelliChairman, President & Chief Executive OfficerPhilippe MarchandChief Operating OfficerAntonino MoralesChief Financial Officer, Secretary & DirectorNathaniel SweedMedical DirectorDarrell TaylorSVP, Chief Legal & Compliance OfficerKey CompetitorsVyant BioNASDAQ:VYNTOpGenNASDAQ:OPGNFresh2 GroupNASDAQ:ANPCFresh2 GroupNASDAQ:FRESPLx PharmaNASDAQ:PLXPView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 20,000 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions BIOC Stock - Frequently Asked Questions Should I buy or sell Biocept stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares. View BIOC analyst ratings or view top-rated stocks. What is Biocept's stock price forecast for 2023? 2 analysts have issued 12 month price objectives for Biocept's stock. Their BIOC share price forecasts range from $120.00 to $120.00. On average, they anticipate the company's share price to reach $120.00 in the next year. This suggests a possible upside of 5,481.4% from the stock's current price. View analysts price targets for BIOC or view top-rated stocks among Wall Street analysts. How have BIOC shares performed in 2023? Biocept's stock was trading at $15.90 at the beginning of 2023. Since then, BIOC shares have decreased by 86.5% and is now trading at $2.15. View the best growth stocks for 2023 here. Are investors shorting Biocept? Biocept saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 7,800 shares, a decline of 24.3% from the April 30th total of 10,300 shares. Based on an average trading volume of 97,800 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.3% of the shares of the company are short sold. View Biocept's Short Interest. When is Biocept's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our BIOC earnings forecast. How were Biocept's earnings last quarter? Biocept, Inc. (NASDAQ:BIOC) posted its earnings results on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million. Biocept had a negative trailing twelve-month return on equity of 235.66% and a negative net margin of 32.99%. During the same quarter in the prior year, the company earned ($12.90) EPS. When did Biocept's stock split? Shares of Biocept reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Michael Nall's approval rating as Biocept's CEO? 4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend. What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST). What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." Who are Biocept's major shareholders? Biocept's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include David F Hale and David F Hale. View institutional ownership trends. How do I buy shares of Biocept? Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $2.15. How much money does Biocept make? Biocept (NASDAQ:BIOC) has a market capitalization of $1.27 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($64.2642) on an earnings per share basis. How many employees does Biocept have? The company employs 104 workers across the globe. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225. This page (NASDAQ:BIOC) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocept, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.